PSCH:NSD-PowerShares S&P SmallCap Health Care Portfolio (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 46.49

Change

0.00 (0.00)%

Market Cap

USD 0.18B

Volume

5.60K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the S&P SmallCap 600? Capped Health Care Index. The fund generally will invest at least 90% of its total assets in common stocks of small capitalization U.S. healthcare companies that comprise the underlying index. These companies are principally engaged in the business of providing healthcare-related products, facilities and services, including biotechnology, pharmaceuticals, medical technology and supplies. The fund is non-diversified.

Inception Date: 07/04/2010

Primary Benchmark: S&P Small 600 Cap HealthCare TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.29%

Management Expense Ratio: 0.29 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Biotechnology ETF 0.47 %

-0.26 (-0.18%)

USD 7.64B
PPH VanEck Pharmaceutical ETF 0.36 %

-1.06 (-1.08%)

USD 0.73B
BBH VanEck Biotech ETF 0.35 %

-0.34 (-0.19%)

USD 0.46B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

-0.21 (-0.45%)

USD 0.15B
GNOM Global X Genomics & Biotechnol.. 0.00 %

+0.19 (+1.69%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

-0.14 (-0.46%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

-0.20 (-1.26%)

USD 0.01B

ETFs Containing PSCH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.62% 25% F 68% D+
Dividend Return 0.24% 60% D- 5% F
Total Return 8.86% 25% F 66% D+
Trailing 12 Months  
Capital Gain 18.66% 63% D 71% C-
Dividend Return 0.27% 33% F 2% F
Total Return 18.93% 63% D 69% C-
Trailing 5 Years  
Capital Gain 17.65% 38% F 61% D-
Dividend Return 0.27% 29% F 1% F
Total Return 17.92% 38% F 55% F
Average Annual (5 Year Horizon)  
Capital Gain 3.67% 50% F 53% F
Dividend Return 3.69% 38% F 50% F
Total Return 0.02% 38% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 29.75% 50% F 62% D
Risk Adjusted Return 12.42% 38% F 49% F
Market Capitalization 0.18B 63% D 48% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.